title: Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status.
abstract: Advanced cancer patients with good performance status (PS) sometimes show poor prognosis despite receiving some chemotherapies. We evaluated prognosis of chemo-naïve advanced biliary tract cancer (ABTC) patients with good PS by Glasgow Prognostic Score (GPS). Sixty-two patients with Eastern Cooperative Oncology Group PS 0 or 1 were retrospectively analyzed, using multivariate Cox regression. GPS was defined with serum levels of two parameters, albumin >3.5 g/dl and C-reactive protein <1.0 mg/dl (both as 0, either as 1, and neither as 2). PS 0 (n = 32) and 1 (n = 30) patients had similar survival (P = 0.98). The median overall survival (OS) was 17.0 months for GPS 0 (n = 19), 14.2 months for GPS 1 (n = 17), and 6.4 months for GPS 2 (n = 26). GPS 2 had significantly shorter OS than GPS 0 (P = 0.002) or 1 (P = 0.033). Multivariate analysis identified two independent prognostic factors: GPS (hazard ratio 0.60, 95 % confidence interval 0.40-0.90, P = 0.012) and liver metastasis (hazard ratio 0.43, 95 % CI 0.20-0.90, P = 0.026). GPS was useful for chemo-naïve ABTC patients with good PS.
authors.affiliation: Division of Gastroenterology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-0006, Japan, tmoriwak@gmail.com.
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Moriwaki
authors.forename: Kazunori
authors.initials: K
authors.lastname: Ishige
authors.forename: Masahiro
authors.initials: M
authors.lastname: Araki
authors.forename: Shigemasa
authors.initials: S
authors.lastname: Yoshida
authors.forename: Masaaki
authors.initials: M
authors.lastname: Nishi
authors.forename: Mikio
authors.initials: M
authors.lastname: Sato
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yamada
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Mitsuharu
authors.initials: M
authors.lastname: Ozeki
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Ishida
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Kenji
authors.initials: K
authors.lastname: Matsuda
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Murashita
authors.forename: Masato
authors.initials: M
authors.lastname: Abei
authors.forename: Ichinosuke
authors.initials: I
authors.lastname: Hyodo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001650:Bile Duct Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D017734:Bile Ducts, Extrahepatic / Q000473:pathology*; D001653:Bile Ducts, Intrahepatic; D001661:Biliary Tract Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D018281:Cholangiocarcinoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends